Literature DB >> 33789873

Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis.

Naomi Tsuchida1,2, Yosuke Kunishita1, Yuri Uchiyama2,3, Yohei Kirino4, Makiko Enaka5, Yukie Yamaguchi6, Masataka Taguri7, Shoji Yamanaka8, Kaoru Takase-Minegishi1, Ryusuke Yoshimi1, Satoshi Fujii5,8, Hideaki Nakajima1, Naomichi Matsumoto2.   

Abstract

OBJECTIVES: To determine clinical and genetic features of individuals with relapsing polychondritis (RP) likely caused by pathogenic somatic variants in ubiquitin-like modifier activating enzyme 1 (UBA1).
METHODS: Fourteen patients with RP who met the Damiani and Levine criteria were recruited (12 men, 2 women; median onset age (IQR) 72.1 years (67.1-78.0)). Sanger sequencing of UBA1 was performed using genomic DNA from peripheral blood leukocytes or bone marrow tissue. Droplet digital PCR (ddPCR) and peptide nucleic acid (PNA)-clamping PCR were used to detect low-prevalence somatic variants. Clinical features of the patients were investigated retrospectively.
RESULTS: UBA1 was examined in 13 of the 14 patients; 73% (8/11) of the male patients had somatic UBA1 variants (c.121A>C, c.121A>G or c.122T>C resulting in p.Met41Leu, p.Met41Val or p.Met41Thr, respectively). All the variant-positive patients had systemic symptoms, including a significantly high prevalence of skin lesions. ddPCR detected low prevalence (0.14%) of somatic variant (c.121A>C) in one female patient, which was subsequently confirmed by PNA-clamping PCR.
CONCLUSIONS: Genetic screening for pathogenic UBA1 variants should be considered in patients with RP, especially male patients with skin lesions. The somatic variant in UBA1 in the female patient is the first to be reported. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  genetic; immune system diseases; polymorphism; systemic vasculitis

Mesh:

Substances:

Year:  2021        PMID: 33789873     DOI: 10.1136/annrheumdis-2021-220089

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

1.  Pathogenic UBA1 variants define a subset of relapsing polychondritis.

Authors:  Jessica McHugh
Journal:  Nat Rev Rheumatol       Date:  2021-06       Impact factor: 20.543

2.  VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome).

Authors:  Ryan J Stubbins; Eric McGinnis; Bhupinder Johal; Luke Yc Chen; Lorena Wilson; Daniela Ospina Cardona; Thomas J Nevill
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

3.  VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis.

Authors:  Francesco Muratore; Chiara Marvisi; Paola Castrignanò; Davide Nicoli; Enrico Farnetti; Orsola Bonanno; Rosina Longo; Piera Zaldini; Elena Galli; Nicholas Balanda; David B Beck; Peter C Grayson; Nicolò Pipitone; Luigi Boiardi; Carlo Salvarani
Journal:  Arthritis Rheumatol       Date:  2022-03-03       Impact factor: 15.483

4.  Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome.

Authors:  Ryan J Stubbins; Hannah Cherniawsky; Luke Y C Chen; Thomas J Nevill
Journal:  CMAJ       Date:  2022-04-11       Impact factor: 8.262

5.  Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.

Authors:  Haruki Matsumoto; Yuya Fujita; Masahiko Fukatsu; Takayuki Ikezoe; Kohei Yokose; Tomoyuki Asano; Naomi Tsuchida; Ayaka Maeda; Shuhei Yoshida; Honami Hashimoto; Jumpei Temmoku; Naoki Matsuoka; Makiko Yashiro-Furuya; Shuzo Sato; Mai Murakami; Hidenori Sato; Chiharu Sakuma; Kazumasa Kawashima; Norshalena Shakespear; Yuri Uchiyama; Hiroshi Watanabe; Yohei Kirino; Naomichi Matsumoto; Kiyoshi Migita
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

6.  Case Report: Tocilizumab Treatment for VEXAS Syndrome With Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study In Japan.

Authors:  Yosuke Kunishita; Yohei Kirino; Naomi Tsuchida; Ayaka Maeda; Yuichiro Sato; Kaoru Takase-Minegishi; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

7. 

Authors:  Ryan J Stubbins; Hannah Cherniawsky; Luke Y C Chen; Thomas J Nevill
Journal:  CMAJ       Date:  2022-09-06       Impact factor: 16.859

8.  Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.

Authors:  Mohamed-Yacine Khitri; Alexis F Guedon; Sophie Georgin-Lavialle; Benjamin Terrier; David Saadoun; Julie Seguier; Maelle le Besnerais; Claire De Moreuil; Guillaume Denis; Mathieu Gerfaud-Valentin; Jean Sebastien Allain; Alexandre Maria; Laurence Bouillet; Vincent Grobost; Joris Galland; Olivier Kosmider; Anael Dumont; Mathilde Devaux; Benjamin Subran; Jean Schmidt; Paola Marianetti-Guingel; Sylvain Audia; Sylvain Palat; Marielle Roux-Sauvat; Vincent Jachiet; Pierre Hirsch; Olivier Fain; Arsène Mekinian
Journal:  RMD Open       Date:  2022-07

Review 9.  Vasculitis associated with VEXAS syndrome: A literature review.

Authors:  Ryu Watanabe; Manami Kiji; Motomu Hashimoto
Journal:  Front Med (Lausanne)       Date:  2022-08-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.